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Background. The neonatal immune system is not fully developed at birth; newborns have adequate lymphocytes counts but these
cells lack function.Objective. To assess the activity of T-cells and the influence of the main perinatal factors in very preterm infants
(birth weight < 1500 g).Design. Blood samples from 59 preterm infants (21/59 were dizygotic twins) were collected at birth and at 30
days of life to measure CD4+ T-cell activity using the ImmuKnow assay. Fifteen healthy adults were included as a control group.
Results. CD4+ T-cell activity was lower in VLBW infants compared with adults (𝑝 < 0.001). Twins showed lower immune activity
compared to singletons (𝑝 = 0.005). Infants born vaginally showed higher CD4+ T-cell activity compared to those born by C-
section (𝑝 = 0.031); infants born after prolonged Premature Rupture of Membranes (pPROM) showed higher CD4+ T-cell activity
at birth (𝑝 = 0.002) compared to infants born without pPROM. Low CD4+ T-cell activity at birth is associated with necrotizing
enterocolitis (NEC) in the first week of life (𝑝 = 0.049). Conclusions. Preterm infants show a lack in CD4+ T-cell activity at birth.
Perinatal factors such as intrauterine inflammation, mode of delivery, and zygosity can influence the adaptive immune activation
capacity at birth and can contribute to exposing these infants to serious complications such as NEC.
1. Introduction
Although the immune system development begins early
during fetal life, its maturation is not completed at birth as
confirmed by the increased susceptibility of newborns and
preterm infants to infectious diseases. The immune system
of the fetus/newborn protects the infant against infection
at the maternal-fetal interface but must also avoid the
potentially harmful proinflammatory/Th1-cell response that
can induce a dangerous reaction between mother and fetus.
Thus, the suppression of proinflammatory response helps the
infant in the transition from the intrauterine environment to
the foreign antigen-rich environment of the outside world.
Therefore this ineffectiveness that has been interpreted for
a long time as a deficiency of the immune system could
represent a biologically advanced response.
The faults of the neonatal immune system are mostly
related to a functional deficit of their components. Newborns
and especially preterm infants have higher leukocyte and
lymphocyte counts compared to adults [1]; however these
cells show poor function at birth as a consequence of the
adaptive immune system not having had strong antigenic
exposure in utero.This is confirmed by the decreased number
of memory T- and B-cells and the increased number of naı̈ve
T- and B-cells in the neonatal bloodstream [2].
In order to measure the immune cell function during the
third trimester of gestation, the immune status in a group of
preterm infants was evaluated at birth and after 30 days of
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life using the ImmuKnow assay (Viracor-IBT Laboratories,
Lee’s Summit, MO). This immunological test measures the
levels of intracellular adenosine triphosphate (iATP) after
in vitro nonspecific stimulation with phytohemoagglutinin
(PHA) asmarker of CD4+T-cell activity; therefore it is one of
the methods for non-pathogen-specific immunemonitoring.
Exposing T-cells to a mitogenic stimulus such as PHA leads
to their metabolic activation and polyclonal expansion, a
process in which the ATP synthesis and release precede
surface receptor expression, cytokine production, and other
subsequent events. Therefore, the iATP levels offer a proxy
for the degree of functionality of the cell-mediated immune
response [3]. The ImmuKnow assay has been cleared by the
US Food and Drug Administration in 2002 for measuring
changes in cell-mediated immunity in solid organ transplant
recipients undergoing immunosuppressive therapy [4] and
now represents one of the few well-established strategies
for functional immune monitoring in the above-mentioned
patient population [3].
Despite that, there are limited reports on the use of
ImmuKnow assay in a pediatric population. Hooper et al.
tested ImmuKnow assay in healthy children aged 1–17 years.
The authors found that children aged 12 years and older
have immune function levels equal to adults, while children
aged less than 12 years present lower immune function levels
compared to adults and older children [5].
However, to the best of our knowledge, ImmuKnow assay
has never been tested in newborns and preterm infants.
The aim of this study was to estimate the peripheral
blood CD4+ T-cell activation rate in response to in vitro
stimulation with PHA in order to assess the basal condition
of the adaptive immune system at birth, its development in
the first month of life, and the influence of the main perinatal
factors on the immune response in a population of very
preterm infants.
2. Methods
2.1. Population. A prospective longitudinal study was carried
out between November 2013 and July 2015 at the Neonatal
Intensive Care Unit (NICU) of St. Orsola-Malpighi Univer-
sity Hospital in Bologna, Italy.
All the infants with gestational age (GA) ≤ 30 weeks and
birth weight (BW) < 1500 g admitted at birth to the NICU
were considered eligible to the study. Infants with congenital
malformations or congenital infections or born to a mother
with pregnancy complications (immunosuppressive disor-
ders, diabetes mellitus, or infections during or preexisting the
pregnancy) were excluded. Before enrollment in the study,
written informed consent was obtained from each of the
infants parents.
Fifteen healthy adults were also included as a control
group.
2.2. Study Design. Peripheral blood samples were collected in
the first day of life and at 30 days of life from each patient to
evaluate the pattern of lymphocytes subpopulations and the
levels of iATP in activated CD4+ T-cells in vitro. Anamnestic
and clinical data were prospectively collected during the
hospital stay.
Sepsis was defined as presence of clinical signs of infec-
tion (worsening of respiratory dynamics, apnea and increased
oxygen requirement, cardiovascular instability with tachycar-
dia or bradycardia, poor perfusion, hypotonia, and shock),
elevation of infections markers (white cell count, CRP, and
procalcitonin), and ≥1 positive blood cultures.
Necrotizing enterocolitis (NEC) was defined according to
Bells modified criteria [6].
The study was approved by the St. Orsola-Malpighi
University Hospital Research Ethics Committee (CIMPre
study, 114/2012/U/Oss).
2.3. Assessment of CD4+ T-Cell Activity and Lymphocyte Sub-
sets. CD4+ T-cell immune response was measured using the
ImmuKnow assay (Viracor-IBT Laboratories, Lee’s Summit,
MO). The test was performed at the Operative Unit of Clin-
ical Microbiology—Laboratory of Virology—of St. Orsola-
Malpighi University Hospital in Bologna, Italy, according to
the package insert.
Peripheral blood was collected in sodium heparin tubes
and processed on the same day. Briefly, 250 𝜇L of whole
blood was diluted with sample diluent, added to wells of a
96-well microtiter plate (12 × 8-well separable strips; one 8-
well strip/each specimen), and incubated for 15–18 h with
PHA in 37∘C in 5% CO
2
. Magnetic particles coated with
anti-human CD4 antibodies were introduced to the wells,
and using a strong magnet, CD4+ T-cells were positively
selected and separated. Then, the cells were lysed to release
intracellular ATP. The released iATP was measured using
luciferin/luciferase reagent and a luminometer.
The patient’s CD4+ T-cell immune response was
expressed as the amount of iATP (ng/mL).
In order to check each assay run, a control specimen
collected from a healthy adult individual (quality control
sample) was processed with patient specimen. Quality con-
trol samples were not included in the adult control group.
The lymphocyte subsets were evaluated using the BD
FACSCalibur Flow Cytometr (BD FACSCaliburTM system,
Becton & Dickson, Mountain View, CA, USA) according to
the manufacturer’s instructions.
2.4. Statistical Analysis. Statistical analysis was performed by
IBM SPSS (Statistical Package for Social Sciences, version
20). Data distribution was checked for normality with the
Shapiro-Wilk test. As the data is not normally distributed,
nonparametric tests were used. Univariate analysis was
performed in order to evaluate which clinical variables
were related to iATP values at birth and at one month
of life: Mann–Whitney and Kruskall-Wallis tests were used
for categorical variables and Spearman correlation test for
continuous variables. Regression multivariate analysis was
performed using as independent variables all those variables
that proved to be significant in the univariate analysis.
Statistical significance was defined as a 𝑝 value < 0.05.
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Table 1: Lymphocytes subpopulations at birth and at 30 days of age of infants enrolled in the study (WBC: white blood cells, N: neutrophils,
L: lymphocytes, and NK: natural killer lymphocytes).
Birth: 59 infants
Median (range)
30 days: 39 infants
Median (range)
WBC (n) 7350 (1170–119200) 10700 (4030–34650)
N (n) 1814 (283–97744) 4267 (908–23562)
N (%) 24.8 (4.3–88) 42 (8.9–75)
L (n) 3775 (903–10775) 4141 (557–10098)
L (%) 60 (6–86.8) 40 (4.4–74)
Pan T (CD3+) 2875 (668–8404.5) 2865 (701–5481)
Pan T (%) 73.9 (47–88) 64.5 (36–84)
CD4+/mL 1954 (388–6680.5) 1982 (438–4725)
CD4+ (% L tot) 54 (32–73) 45.5 (20–69)
CD8+ mL 673 (172–2312) 729.5 (198–2650.5)
CD8+ (% L tot) 18 (8–32) 16 (8–45)
CD4+/CD8+ 2.92 (1.37–7.38) 2.67 (0.77–6.25)
NK/mL 242.25 (35.6–1536) 442.75 (15–1371)
NK (% L tot) 7 (1–24) 9.5 (1–42)
Pan B/mL 501 (60.56–3770) 829.35 (210–3635.3)
Pan B (%) 15 (2–30.6) 22.9 (9–41)
3. Results
Seventy-three eligible infants were admitted to NICU during
the study period. Fourteen infants (19,1%) were excluded
because they either fulfilled the exclusion criteria (4 cases of
congenital heart disease and 4 cases of polymalformations) or
peripheral blood samples could not be collected within the
first day of life (4 infants died and 2 were transferred from
our unit in the first days of life). The study was carried out in
a population of 59 preterm infants with GA ≤ 30 weeks and
BW< 1500 g; 21/59were dizygotic twins (the study population
does not include monozygotic twins).
Samples were obtained at 30 days of life from 39/59
(66.1%) of the recruited newborns; the remaining 20/59
(33.8%) encountered death (4 infants) or were transferred to
other hospitals before 30 days of life.
3.1. Lymphocyte Subsets. Thepattern of lymphocytes subpop-
ulations at birth and at 30 days of life is reported in Table 1.
We found no significant difference between the absolute cell
count at birth and at the end of the first month of life. While
the absolute number of CD4+ T-cells did not correlate to
the median value of iATP at birth (𝑝 = 0.831) a significant
positive correlation was observed at 30 days of life (𝑝 =
0.011).
3.2. CD4+ Activity in Preterm Newborns at Birth and 30
Days of Age Compared to Adult Controls. While there were
no significant differences in CD4+ T-cells ATP levels at
birth versus 30 days of life (median: 100 ng/mL [range:
6–733 ng/mL] versus 168 ng/mL [range: 3–383 ng/mL];




















Figure 1: CD4+ T-cell activity (median iATP values) in preterm
infants and in adult controls (d0: evaluation at birth; m1: evaluation
at 30 days of life). Outliers are marked as ∘ (“out values”: 1,5–3 ×
interquartile range, IQR) and ∗ (“extreme values”: > 3 × IQR).
compared to adults controls (𝑝 < 0.001) as shown in
Figure 1.
3.3. Perinatal Factors and CD4+ Activity. Univariate analysis
showed no significant correlation between median Immu-
Know iATP levels at birth and GA, BW, gender, intrauterine
growth retardation (SGA, small for gestational age), and use
of prenatal steroids (Table 2).
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Table 2: Characteristics at birth of infants enrolled in the study: median (range); GA: gestational age; SGA: small for gestational age; AGA:
appropriate for gestational age; ∗∗∗pPROM: prolonged Premature Rupture ofMembranes: a case of premature rupture ofmembranes in which
more than 18 hours has passed between the rupture and the onset of labor/delivery.
Birth
(59 infants) 𝑝 value
30 days of life
(39 infants) 𝑝 value
Gestational age, weeks, mean ± DS 27.7 ± 2.4 27.5 ± 2.2
Birth weight, mean ± DS (g) 992 ± 297 981 ± 281
Gender male, infants number (%) 33 (55.9) 23 (59.0)




Female sex, mean ± DS (iATP ng/mL) 110 ± 140.6 187 ± 105
Singleton, infants number (%) 38 (64.4) 25 (64.1)




Twins: iATP ng/mL∧ 84 (26–153) 168 (10–365)
Small for GA, infants number (%) 10 (16.9) 6 (15.4)




AGA, mean ± DS (iATP ng/mL) 164 ± 158 177 ± 120
Vaginal delivery, infants number (%) 28 (47.5) 19 (48.7)




Cesarean delivery: iATP ng/mL∧ 83 (6–352) 215 (3–292)
pPROM∗∗∗, infants number (%) 15 (25.4) 9 (23.0)




All others conditions: iATP ng/mL∧ 87 (6–733) 168.5 (3–365)
Prenatal steroids, infants number (%) 48 (81.3) 33 (84.6)




No prenatal steroids, mean ± DS (iATP ng/mL) 79 ± 52 117 ± 95
∧ means that the values are expressed as median and range (brackets) instead of mean ± standard deviation.
The twenty-one twins showed significantly lower median
ImmuKnow iATP levels at birth compared to the remaining
38 singleton infants (𝑝 = 0.005); this difference was no longer
significant at 30 days of life (Table 2 and Figure 2(a)).
Infants born to vaginal delivery had higher median ATP
levels produced by activated CD4+ T-cells at birth compared
to those born to C-section (𝑝 = 0.031); no difference was
found at 30 days of life (Table 2).
Fifteen out of 59 preterm infants were born to mothers
with pPROM (prolonged Premature Rupture of Membranes
> 18 hrs); these infants showed a higher activity of CD4+ T-
cells at birth compared to the 44 remaining infants (𝑝 =
0.002); this difference disappeared at 30 days of life (Table 2
and Figure 2(b)).
A multivariate analysis was performed including those
variables (pPROM and twin pregnancy) which proved to be
significant in the univariate analysis: both pPROM (Stan-
dardized Beta = 0.344, 𝑡 = 2.875, and 𝑝 = 0.006) and twin
pregnancies (Standardized Beta = −0.359, 𝑡 = −3.008, and
𝑝 = 0.004) were found to be independently associated with
ImmuKnow iATP levels at birth (higher and lower values,
resp.).
3.4. Morbidity during the First 30 Days of Hospital Stay and
CD4+ Activity. No correlation was found between CD4+ T-
cell activity at birth or at 30 days of life and mechanical
ventilation, patency of ductus arteriosus, early onset sepsis,
late onset sepsis, postnatal steroids, antibiotics use, type of
enteral nutrition, and death.
Five out of 59 (8.5%) preterm infants developed NEC
≥ stage 3 during the first week of life; these infants had
significantly lower median iATP values at birth compared to
the 55 infants without NEC (𝑝 = 0.049) (Figure 2(c)).We also
performed a subgroup analysis dividing the infants into three
subgroups according to gestational age (23-24, 25–27, and 28–
30 weeks). We found that three out 5 infants who developed
NEC were in the 23-24 weeks subgroup and the remaining
two were in the 25–27 weeks one. In the 23-24 weeks group,
there was still a significant difference in terms of immune cell
function between infants who did and did not develop NEC
(𝑝 = 0.036). On the contrary, the difference of median iATP
levels between infants who did and did not develop NEC in
the 25–27 weeks group was not significant, but we can not
exclude the possibility that this is a consequence of the little
data we had available.
No difference inCD4+T-cell activitywas found at 30 days
of life in relation to NEC condition.
3.5. Short-Term Outcomes and CD4+ Activity. We found no
influence of CD4+ T-cell activity on short-term outcomes
(IVH: intraventricular hemorrhage; PVL: periventricular































































Figure 2: Levels of ATP at birth: (a) in twins and singleton; (b) pPROM versus other conditions of delivery; (c) patients with and without
NEC. Outliers are marked as ∘ (“out values”: 1,5–3 × interquartile range, IQR) and ∗ (“extreme values”: > 3 × IQR).
leukomalacia; ROP: retinopathy of prematurity; BPD: Bron-
chopulmonary Dysplasia; death), at birth or at 30 days of life.
4. Discussion
The neonatal immune system is not fully developed at birth
and newborns are therefore exposed to the risk of infection by
a large number of viruses, bacteria, protozoa, and fungi. This
weakness can be partly attributed to the lack of preexisting
immunological memory and competent adaptive immunity.
Newborn infants have deficiencies in T-cell activation and
cytokine production, B-cell immunoglobulin production,
and interactions between T- and B-cells, when compared to
adults [7]. T-lymphocytes, especially CD4+ T-cells, play a
crucial role in the regulation of the immune system. They
are often targeted as a marker of the global immune function
because they are involved in the modulation of the adaptive
immunity, both humoral and cell-mediated, and they also
play an important role in the control of innate immune
response.
From 19 weeks of gestation, T-cell subpopulations grad-
ually increase in number and continue to rise after birth to
peak at about 6–9 months of life. The numbers subsequently
decline, to reach adult levels at 6-7 years of age [8]. In term
neonates, CD4+ T-cells constitute a higher proportion of T-
cells than adults. CD8+ T-cells on the other hand are fewer
both in terms of absolute number and as a percentage of total
T-cells. Preterm infants have a significantly higher number
of CD4+ T-cells while the number of CD8+ T-cells does not
seem to change with gestational age [9]. Reference values for
T-lymphocyte count are established for all ages but they do
not reflect cell function.
In this study, we used the ImmuKnow assay in order
to investigate the function of CD4+ T-cells at birth in a
population of preterm infants.This test is one of the methods
for non-pathogen-specific immunemonitoring andmeasures
the levels of ATP produced by CD4+ T-cells in response
to in vitro stimulation with a nonspecific mitogen such as
PHA [4]. ATP production is the final response of CD4+ cells
that is common to different nonspecific factors. ATP is a key
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metabolic marker; it is produced within minutes to hours
of initial stimulation and is necessary for cellular function
regardless of eventual effector function and therefore it is
a highly suitable marker for T-lymphocyte activation and
a clinical evaluation of global T-lymphocyte function [10].
At this moment there are no certainties regarding if the
low ATP production by premature CD4 cells is due to
inherent immaturity of ATP production, signaling, imma-
ture proliferation mechanism, or something else. However,
some authors [11–15] suggest that the inability of neonatal
CD4+ T-cells to go towards an efficient activation may
be related/caused by an impaired process of signaling. A
limit of the ImmuKnow assay is the lack of specificity,
because PHA cause a nonspecific mitogenic stimulation
that can not define any specific aspect of the immune
response, like cytokine expression that marks Th1 or Th2
activation; but its major advantage is that it is clinically
available unlike most other immunological assays. Immu-
Know assay has previously only been tested in adults and
children and this is the first study that uses this assay to
assess T-cell-mediated immunity in preterm infants.This test
seemed quite suitable for preterm infants since it requires
a very small amount of peripheral blood to be performed
(250𝜇L).
Our findings show similar leukocyte and CD4+ T-cells
counts to previously reported studies in preterm population
[2, 16].
Wedocumented a lack of association between the number
of CD4+ T-cells at birth and their function (measured by
intracellular ATP production) and a positive correlation
between number and activity of CD4+ T-cells at 30 days of
life. Whether there is or there is no correlation between the
number of lymphocytes and their function is still a matter of
debate in literature.
Kowalski et al. [10] demonstrated that this correlation is
weak (𝑟 = 0.24), emphasizing the usefulness of ImmuKnow
assay to provide a quantification of CD4+ T-cells activity that
is independent of cells absolute number.
However, other studies performed afterwards questioned
this observation since a positive association between white
blood cell count and ImmuKnow levels was observed [17, 18].
Dharnidharka andHesemann suggest that this may represent
an underappreciated limitation of the ImmuKnow test since
the levels of ATP are expressed as a concentration (ng/mL)
without accounting for the number of white blood cells
present in the volume of sample tested [19].
Because each study is heterogeneous from the other,
differing in characteristics such as population, type of organ
transplant, immunosuppression protocols, and timing of
ImmuKnow assay it is difficult to come to conclusions.
We hypothesized that the correlation in our study is
initially absent as a consequence of the immunological
immaturity at birth (lymphocytes may be present in the
bloodwithout being functional) and becomes significant over
time with the functional maturation of lymphocytes. Other
neonatal confounding factors may also play a role and cannot
be excluded and larger studies on immunocompetent subjects
may validate our hypothesis.
In our study the adult control population includes healthy
HIV-seronegative immunocompetent people, whose lym-
phocytes subpopulations related data are not available.
We found that preterm infants have a reduced CD4+ T-
cell activation capacity compared to adults: the iATP values
at birth are low, and despite a trend towards higher values
over time, they remain significantly lower at 30 days of life.
It is known that newborns, especially preterm infants, have
deficiencies in both innate and adaptive immunity and many
studies have demonstrated lower concentrations of cytokines
such as TNF-𝛼, IFN-𝛼, IL-4, IL-5, IL-10, IL-15, and IFN-𝛾 in
preterm infants’ blood compared to adults [20–23]. However
cytokines production is an indirect estimate of cellular
function.The present study sets the functional impairment of
CD4+ T-cells at the initial steps of T-lymphocyte activation,
when ATP is produced. Since ATP is a basic energy source
within cells, its production is an essential requirement for all
lymphocytes function following activation [10].
In this study twin infants showed median ImmuKnow
iATP levels at birth much lower compared to singletons.This
is an interesting find and literature lacks information on the
immunological peculiarities of multiple pregnancies. All the
twins included in the study were dizygotic and thus immuno-
logically different. We hypothesize that, in addition to a gen-
eralized status of immunological deficiency or insufficiency,
the copresence of twins in uteromay induce a deeper immune
tolerance that involves both fetuses and the mother in order
to avoid the potentially harmful immune reaction between
the three. Our hypothesis is in accordance with previous
studies that documented higher levels of Th2-cytokines in
the blood ofmothers carrying twins comparedwith singleton
pregnancies [24] underlining the more profound Th1-Th2
shift that occurs in twin pregnancies.Moreover, a recent study
demonstrated that both dizygotic twins and theirmothers are
more prone to infection than monozygotic twins, singletons,
and their mothers [25].
We found that pPROM significantly increases CD4+ T-
cells activation at birth. This data is consistent with previous
findings that reported that lymphocytes are activated during
infections in utero, indicating that fetal adaptive immune
response is at least partly responsive [26]. It has been shown
that bacteria and proinflammatory mediators in amniotic
fluid can elicit a fetal inflammatory response, documented
by an increase in fetal plasma cytokines and C reactive
protein [27–29]. Fetuses andneonates exposed to intrauterine
inflammation have increasedTh1 cells response and increased
levels of IFN-𝛾, indicating a potential shift fromTh2 toTh1 of
the fetus [7, 30].
We have also demonstrated that CD4+ T-cell activity at
birth is increased in infants born after a vaginal delivery.
Increasing evidence suggests that parturition itself is an
inflammatory event [31].
Our findings support the current knowledge that
intrauterine inflammation/infection can lead to immune
maturation in the fetus. But these differences disappear at 30
days of life most likely because all the categories (pPROM
versus non-pPROM and vaginal delivery versus cesarean
section) are exposed to the same extrauterine environment.
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In our study population, the levels of iATP at birth did
not correlate with the risk of sepsis. This is not the first study
that fails to detect an association between low ImmuKnow
iATP values and infection. Regarding this topic, previous
studies performed in immunocompromised adults showed
conflicting results [32]. In fact in the transplant setting,
some authors reported that the ImmuKnow assay was not
able to identify individuals at risk of infection, while others
found that the assay was a useful tool for assessing this risk
[33, 34].
Significant positive correlations were observed between
low CD4+ T-cell activation capacity at birth and NEC devel-
opment in the first week of life. Although the etiopathogene-
sis of NEC is still amatter of debate, some authors support the
involvement of innate immune system [35]. We hypothesize
that an impairment of the adaptive immune system may also
play a role in the altered immune reaction that leads to NEC
development. CD4+ T-cells impaired function may hinder
infection control in the intestinal lumen. Other mechanisms
may also be involved and a more detailed characterization
of CD4+ T-cells is needed to clarify their role in the NEC
pathogenesis.
This study has some limitations.The study sample is small
and lacks control groups both at term andwith gestational age
> 30 weeks.
Another limitation is the absence of an immunophe-
notypic classification of CD4+ T-cells. The evaluation of
Treg cells is crucial to understanding the immunological
characteristics of the preterm infants.These CD4+ T-cells are
provided with immunosuppressive functions and represent
a high proportion of lymphocytes at birth with a significant
inverse correlation with GA [9]. The role of Treg cells in the
modulation of the immune response is an expanding field of
research and this data can add precious information to our
findings.
In conclusion, preterm infants show a lack in CD4+
T-cells activation and fail to show a functional matu-
ration of lymphocytes over the first month of life. An
impaired ability to respond to stimulation can contribute
to expose these infants to serious complications such as
NEC. However, the adaptive immune response can at least
partially be elicited during the fetal life by events occur-
ring before delivery such as pPROM or vaginal delivery.
Further studies in larger populations are needed to clarify
these results and to better understand the cellular mecha-
nism that regulates neonatal adaptive immune response to
pathogens.
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[25] J. Spiegler, C. Härtel, L. Schulz et al., “Causes of delivery and
outcomes of very preterm twins stratified to zygosity,” Twin
Research and Human Genetics, vol. 15, no. 4, pp. 532–536, 2012.
[26] P. J. Duggan, E. F. Maalouf, T. L.Watts et al., “Intrauterine T-cell
activation and increased proinflammatory cytokine concentra-
tions in preterm infants with cerebral lesions,” The Lancet, vol.
358, no. 9294, pp. 1699–1700, 2001.
[27] S. M. Berry, R. Romero, R. Gomez et al., “Premature parturition
is characterized by in utero activation of the fetal immune
system,” American Journal of Obstetrics & Gynecology, vol. 173,
no. 4, pp. 1315–1320, 1995.
[28] R. L.Goldenberg, J. C.Hauth, andW.W.Andrews, “Intrauterine
infection and preterm delivery,” The New England Journal of
Medicine, vol. 342, no. 20, pp. 1500–1507, 2000.
[29] F. Gotsch, R. Romero, J. P. Kusanovic et al., “The fetal inflam-
matory response syndrome,”Clinical Obstetrics andGynecology,
vol. 50, no. 3, pp. 652–683, 2007.
[30] L. Sykes, D. A.MacIntyre, X. J. Yap, T.G. Teoh, and P. R. Bennett,
“The Th1:Th2 dichotomy of pregnancy and preterm labour,”
Mediators of Inflammation, vol. 2012, Article ID 967629, 2012.
[31] J. E. Norman, S. Bollapragada, M. Yuan, and S. M. Nelson,
“Inflammatory pathways in the mechanism of parturition,”
BMC Pregnancy and Childbirth, vol. 7, supplement 1, article S7,
2007.
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